AF9 anticorps (Middle Region)
-
- Antigène Voir toutes AF9 (MLLT3) Anticorps
- AF9 (MLLT3) (Protein AF-9 (MLLT3))
-
Épitope
- Middle Region
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp AF9 est non-conjugé
-
Application
- Western Blotting (WB), Enzyme Immunoassay (EIA)
- Specificité
- This antibody reacts to AF9 (MLLT3).
- Purification
- Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS
- Immunogène
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the center region of human MLLT3.
- Isotype
- Ig Fraction
- Top Product
- Discover our top product MLLT3 Anticorps primaire
-
-
- Indications d'application
-
ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 0.25 mg/mL
- Buffer
- PBS with 0.09 % (W/V) sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freezing and thawing.
- Stock
- 4 °C/-20 °C
- Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
- Antigène
- AF9 (MLLT3) (Protein AF-9 (MLLT3))
- Autre désignation
- MLLT3 / AF9 (MLLT3 Produits)
- Synonymes
- anticorps fc39c11, anticorps wu:fc39c11, anticorps zgc:110210, anticorps AF9, anticorps YEATS3, anticorps 2210011H10Rik, anticorps 2610012I03Rik, anticorps 3830408D16Rik, anticorps Af9, anticorps D4Ertd321e, anticorps Af-9, anticorps MLLT3, super elongation complex subunit, anticorps myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3, anticorps mllt3, anticorps MLLT3, anticorps Mllt3
- Sujet
- The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.Synonyms: ALL1 fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, Protein AF-9, YEATS domain-containing protein 3, YEATS3
- ID gène
- 4300, 9606
- UniProt
- P42568
-